IBDEI1DP ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24430,1,1,0)
 ;;=1^710.0
 ;;^UTILITY(U,$J,358.3,24430,1,2,0)
 ;;=2^SYST LUPUS ERYTHEMATOSIS
 ;;^UTILITY(U,$J,358.3,24430,2)
 ;;=^72159
 ;;^UTILITY(U,$J,358.3,24431,0)
 ;;=710.1^^136^1494^18
 ;;^UTILITY(U,$J,358.3,24431,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24431,1,1,0)
 ;;=1^710.1
 ;;^UTILITY(U,$J,358.3,24431,1,2,0)
 ;;=2^SYSTEMIC SCLEROSIS
 ;;^UTILITY(U,$J,358.3,24431,2)
 ;;=^108590
 ;;^UTILITY(U,$J,358.3,24432,0)
 ;;=446.7^^136^1494^19
 ;;^UTILITY(U,$J,358.3,24432,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24432,1,1,0)
 ;;=1^446.7
 ;;^UTILITY(U,$J,358.3,24432,1,2,0)
 ;;=2^TAKAYASU'S DISEASE
 ;;^UTILITY(U,$J,358.3,24432,2)
 ;;=^117141
 ;;^UTILITY(U,$J,358.3,24433,0)
 ;;=446.6^^136^1494^20
 ;;^UTILITY(U,$J,358.3,24433,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24433,1,1,0)
 ;;=1^446.6
 ;;^UTILITY(U,$J,358.3,24433,1,2,0)
 ;;=2^THROMBOT MICROANGIOPATHY
 ;;^UTILITY(U,$J,358.3,24433,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,24434,0)
 ;;=446.4^^136^1494^22
 ;;^UTILITY(U,$J,358.3,24434,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24434,1,1,0)
 ;;=1^446.4
 ;;^UTILITY(U,$J,358.3,24434,1,2,0)
 ;;=2^WEGENER'S GRANULOMATOSIS
 ;;^UTILITY(U,$J,358.3,24434,2)
 ;;=^127623
 ;;^UTILITY(U,$J,358.3,24435,0)
 ;;=444.9^^136^1494^4
 ;;^UTILITY(U,$J,358.3,24435,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24435,1,1,0)
 ;;=1^444.9
 ;;^UTILITY(U,$J,358.3,24435,1,2,0)
 ;;=2^ARTERIAL EMB/THROMBOSIS NEC
 ;;^UTILITY(U,$J,358.3,24435,2)
 ;;=^39452
 ;;^UTILITY(U,$J,358.3,24436,0)
 ;;=710.9^^136^1494^5
 ;;^UTILITY(U,$J,358.3,24436,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24436,1,1,0)
 ;;=1^710.9
 ;;^UTILITY(U,$J,358.3,24436,1,2,0)
 ;;=2^CONNECTIVE TISSUE DISEASE NEC
 ;;^UTILITY(U,$J,358.3,24436,2)
 ;;=^123811
 ;;^UTILITY(U,$J,358.3,24437,0)
 ;;=453.9^^136^1494^21
 ;;^UTILITY(U,$J,358.3,24437,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24437,1,1,0)
 ;;=1^453.9
 ;;^UTILITY(U,$J,358.3,24437,1,2,0)
 ;;=2^VENOUS EMB/THROMBOSIS NEC
 ;;^UTILITY(U,$J,358.3,24437,2)
 ;;=^39455
 ;;^UTILITY(U,$J,358.3,24438,0)
 ;;=441.00^^136^1494^1
 ;;^UTILITY(U,$J,358.3,24438,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24438,1,1,0)
 ;;=1^441.00
 ;;^UTILITY(U,$J,358.3,24438,1,2,0)
 ;;=2^ANEURYSM,AORTIC W/ DISSECTION,SITE UNSPEC
 ;;^UTILITY(U,$J,358.3,24438,2)
 ;;=^35660
 ;;^UTILITY(U,$J,358.3,24439,0)
 ;;=042.^^136^1495^1
 ;;^UTILITY(U,$J,358.3,24439,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24439,1,1,0)
 ;;=1^042.
 ;;^UTILITY(U,$J,358.3,24439,1,2,0)
 ;;=2^AIDS OR HIV INFECTION,SYMPTOMATIC
 ;;^UTILITY(U,$J,358.3,24439,2)
 ;;=^266500
 ;;^UTILITY(U,$J,358.3,24440,0)
 ;;=540.9^^136^1495^2
 ;;^UTILITY(U,$J,358.3,24440,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24440,1,1,0)
 ;;=1^540.9
 ;;^UTILITY(U,$J,358.3,24440,1,2,0)
 ;;=2^APPENDICITIS,ACUTE
 ;;^UTILITY(U,$J,358.3,24440,2)
 ;;=^270195
 ;;^UTILITY(U,$J,358.3,24441,0)
 ;;=682.9^^136^1495^3
 ;;^UTILITY(U,$J,358.3,24441,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24441,1,1,0)
 ;;=1^682.9
 ;;^UTILITY(U,$J,358.3,24441,1,2,0)
 ;;=2^CELLULITIS AND ABSCESS,SITE NOS
 ;;^UTILITY(U,$J,358.3,24441,2)
 ;;=^21160
 ;;^UTILITY(U,$J,358.3,24442,0)
 ;;=576.1^^136^1495^4
 ;;^UTILITY(U,$J,358.3,24442,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24442,1,1,0)
 ;;=1^576.1
 ;;^UTILITY(U,$J,358.3,24442,1,2,0)
 ;;=2^CHOLANGITIS
 ;;^UTILITY(U,$J,358.3,24442,2)
 ;;=^23291
 ;;^UTILITY(U,$J,358.3,24443,0)
 ;;=574.70^^136^1495^5
 ;;^UTILITY(U,$J,358.3,24443,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24443,1,1,0)
 ;;=1^574.70
 ;;^UTILITY(U,$J,358.3,24443,1,2,0)
 ;;=2^CHOLECYSTITIS
 ;;^UTILITY(U,$J,358.3,24443,2)
 ;;=^304314
 ;;
 ;;$END ROU IBDEI1DP
